APA (7th ed.) Citation

Maréchal, C., Lal, H., Poder, A., Ferguson, M., Enweonye, I., Heineman, T. C., . . . Oostvogels, L. (2019). Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278–4286]. Vaccine, 37(9), 1252. https://doi.org/10.1016/j.vaccine.2019.01.022

Chicago Style (17th ed.) Citation

Maréchal, Céline, et al. "Corrigendum to 'Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine Co-administered with the 23-valent Pneumococcal Polysaccharide Vaccine in Adults ≥50 years of Age: A Randomized Trial' [Vaccine 36 (2018) 4278–4286]." Vaccine 37, no. 9 (2019): 1252. https://doi.org/10.1016/j.vaccine.2019.01.022.

MLA (9th ed.) Citation

Maréchal, Céline, et al. "Corrigendum to 'Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine Co-administered with the 23-valent Pneumococcal Polysaccharide Vaccine in Adults ≥50 years of Age: A Randomized Trial' [Vaccine 36 (2018) 4278–4286]." Vaccine, vol. 37, no. 9, 2019, p. 1252, https://doi.org/10.1016/j.vaccine.2019.01.022.